Skip to main content
Livermore
Livermore
ZHEN

Empery Asset Management, LP

SEC CIK
0001469336
Latest filing
Aug 11, 2026

The latest 13F from Empery Asset Management, LP covers Q2 2026 (filed Aug 11, 2026): 32 long positions worth $86.5M. The top 10 holdings make up 90.7% of the portfolio, and the largest is X4 Pharmaceuticals, Inc (XFOR) at 37.4%. Livermore has 7 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
11
Est. +$28.8M
Added
0
Reduced
8
Est. −$21.7M
Sold out
11
Est. −$9.00M

Top 5 holdings

Share of this quarter's portfolio value

  1. XFORX4 Pharmaceuticals, Inc
    37.4%$32.4MHistory
  2. EMPDEmpery Digital Inc.
    12.1%$10.4MHistory
  3. NGENNervgen Pharma Corp.
    9.5%$8.24MHistory
  4. DTILPrecision Biosciences Inc
    7.1%$6.10MHistory
  5. CLNNClene Inc.
    6.5%$5.64MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. NGENNervgen Pharma Corp.
    +$8.24MNewHistory
  2. CLNNClene Inc.
    +$5.64MNewHistory
  3. ANVSAnnovis Bio, Inc.
    +$4.47MNewHistory
  4. LTRNLantern Pharma Inc.
    +$3.51MNewHistory
  5. AMCAMC Entertainment Holdings, Inc.
    +$3.26MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. NGENNervgen Pharma Corp.
    +9.53 pp0.0% → 9.5%History
  2. CLNNClene Inc.
    +6.52 pp0.0% → 6.5%History
  3. ANVSAnnovis Bio, Inc.
    +5.17 pp0.0% → 5.2%History
  4. LTRNLantern Pharma Inc.
    +4.06 pp0.0% → 4.1%History
  5. AMCAMC Entertainment Holdings, Inc.
    +3.77 pp0.0% → 3.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. XFORX4 Pharmaceuticals, Inc
    −$9.40MReducedHistory
  2. DTILPrecision Biosciences Inc
    −$9.38MReducedHistory
  3. IMPPImperial Petroleum Inc./Marshall Islands
    −$3.76MSold outHistory
  4. BSINBig Sky Industrial Inc.
    −$1.70MSold outHistory
  5. VENUVenu Holding Corp
    −$1.12MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. XFORX4 Pharmaceuticals, Inc
    −7.07 pp44.5% → 37.4%History
  2. DTILPrecision Biosciences Inc
    −5.99 pp13.0% → 7.1%History
  3. IMPPImperial Petroleum Inc./Marshall Islands
    −4.52 pp4.5% → 0.0%History
  4. VENUVenu Holding Corp
    −2.67 pp4.0% → 1.3%History
  5. BSINBig Sky Industrial Inc.
    −2.04 pp2.0% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$86.5M
+$3.46M (+4.2%) vs. prior quarter
Positions
32
0 vs. prior quarter
Top 10 concentration
90.7%
Top 10 as share of value
Turnover
33.9%
Q2 2026, one quarter
Average holding period
2.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

7 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $113.4M (Q4 2025)

Q4 2021: $47.9MQ1 2022: $21.3MQ2 2022: $18.5MQ3 2022: $16.8MQ4 2025: $113.4MQ1 2026: $83.0MQ2 2026: $86.5M
Q4 2021Q2 2026
13F filings of Empery Asset Management, LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 11, 202632$86.5MXFOREMPDNGENvs. Q1 2026SEC
Q1 2026May 8, 202632$83.0MXFOREMPDDTILvs. Q4 2025SEC
Q4 2025Feb 11, 202631$113.4MXFORIMRXEMPD–SEC
Q3 2022Nov 14, 202288$16.8METNBUBXFat Brands, Incvs. Q2 2022SEC
Q2 2022Aug 12, 202275$18.5MMMAT1847 Goedeker IncSLSvs. Q1 2022SEC
Q1 2022May 16, 202277$21.3M1847 Goedeker IncTC BioPharm (Holdings) plcFat Brands, Incvs. Q4 2021SEC
Q4 2021Feb 11, 202270$47.9M1847 Goedeker IncSRZNISPC–SEC

13D and 13G filings

Companies where Empery Asset Management, LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

7 companies, largest stake first.

Companies where Empery Asset Management, LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
EMPDEmpery Digital Inc.13D/A17.51%4.93M shares+1.75 ppfrom 15.76%Jan 13, 202310 filingsSep 3, 2026SEC
XFORX4 Pharmaceuticals, Inc13G/A9.99%9.04M shares0.00 ppfrom 9.99%Jan 13, 20234 filingsJan 15, 2026SEC
CYNCyngn Inc.13G9.99%1.40M shares+9.99 ppfrom 0.00%Jan 10, 20245 filingsApr 22, 2026SEC
LTRNLantern Pharma Inc.13G9.99%1.32M shares–Jan 25, 20213 filingsAug 4, 2026SEC
CLRBCellectar Biosciences, Inc.13G9.99%864.1K sharesNewAug 4, 20261 filingAug 4, 2026SEC
CLNNClene Inc.13G7.17%916.5K sharesNewAug 4, 20261 filingAug 4, 2026SEC
ANVSAnnovis Bio, Inc.13G5.64%2.40M sharesNewJul 29, 20261 filingJul 29, 2026SEC

Latest filings

181 filings on file made by Empery Asset Management, LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Empery Asset Management, LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
EMPDEmpery Digital Inc.Sep 3, 202610:30 AM ET13D/A17.51%4.93M shares+1.75 ppfrom 15.76%Sep 1, 2026SEC
EMPDEmpery Digital Inc.Aug 14, 20261:02 PM ET13D/A15.76%4.43M shares+6.79 ppfrom 8.97%Aug 12, 2026SEC
CLNNClene Inc.Aug 4, 202610:08 AM ET13G7.17%916.5K sharesNewJun 30, 2026SEC
CLRBCellectar Biosciences, Inc.Aug 4, 202610:06 AM ET13G9.99%864.1K sharesNewJun 30, 2026SEC
LTRNLantern Pharma Inc.Aug 4, 202610:03 AM ET13G9.99%1.32M shares–Jun 30, 2026SEC
ANVSAnnovis Bio, Inc.Jul 29, 20264:17 PM ET13G5.64%2.40M sharesNewJun 30, 2026SEC
ABTSAbits Group IncJul 29, 20264:16 PM ET13G/A0.00%0 shares−9.99 ppfrom 9.99%Below 5%Jun 30, 2026SEC
SLESuper League Enterprise, Inc.Jul 29, 20264:16 PM ET13G/A4.99%85.9K shares−5.00 ppfrom 9.99%Below 5%Jun 30, 2026SEC
DTILPrecision Biosciences IncJul 29, 20264:15 PM ET13G/A4.99%1.31M shares−2.64 ppfrom 7.63%Below 5%Jun 30, 2026SEC
CYNCyngn Inc.Apr 22, 20269:01 AM ET13G9.99%1.40M shares+9.99 ppfrom 0.00%Mar 31, 2026SEC
ABTSAbits Group IncApr 22, 20269:00 AM ET13G9.99%273.8K sharesNewMar 31, 2026SEC
IMPPImperial Petroleum Inc./Marshall IslandsApr 15, 20269:46 AM ET13G/A4.99%2.30M shares−2.14 ppfrom 7.13%Below 5%Mar 31, 2026SEC
DTILPrecision Biosciences IncApr 15, 20269:46 AM ET13G/A7.63%1.97M shares−2.36 ppfrom 9.99%Mar 31, 2026SEC
RBNERobin Energy Ltd.Apr 15, 20269:45 AM ET13G/A0.00%0 shares−9.99 ppfrom 9.99%Below 5%Mar 31, 2026SEC
IMPPImperial Petroleum Inc./Marshall IslandsJan 28, 202610:38 AM ET13G7.13%3.18M sharesNewDec 31, 2025SEC
RBNERobin Energy Ltd.Jan 28, 202610:35 AM ET13G9.99%306.6K sharesNewDec 31, 2025SEC
DTILPrecision Biosciences IncJan 22, 20261:01 PM ET13G9.99%2.30M sharesNewDec 31, 2025SEC
SLESuper League Enterprise, Inc.Jan 22, 202612:56 PM ET13G9.99%1.28M sharesNewDec 31, 2025SEC
IMRXImmuneering CorpJan 15, 20261:23 PM ET13G/A4.99%3.25M shares−3.84 ppfrom 8.83%Below 5%Dec 31, 2025SEC
XFORX4 Pharmaceuticals, IncJan 15, 20261:21 PM ET13G/A9.99%9.04M shares0.00 ppfrom 9.99%Dec 31, 2025SEC